DRKS00027912招募中不适用
Dose-optimized stereotactic body radiotherapy for locally advanced or recurrent pancreatic andenocarcinoma - ORP 001
ordstrahl0 个研究点目标入组 30 人开始时间: 2022年9月9日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 99 Years（—）
- 性别
- All
入选标准
- •Locally advanced pancreatic cancer
- •- recurrent pancreatic cancer
排除标准
- •-previous Radiotherapy
- •-more advanced stadium than oligometastatic disease
- •-PTV more than 75 ml
研究者
相似试验
招募中
不适用
Stereotactic Body Radiotherapy for the Management of Prostate Cancer Local RecurrencesC61Malignant neoplasm of prostateDRKS00030837Europäisches Radiochirurgie Centrum München50
进行中（未招募）
1 期
Addition of stereotactic body radiotherapy (SBRT) to chemotherapy in locally advanced biliary tract cancersocally advanced biliary tract cancerMedDRA version: 21.0Level: LLTClassification code 10004586Term: Bile duct adenocarcinoma non-resectableSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 100000004864EUCTR2014-003656-31-GBniversity College London81
进行中（未招募）
不适用
A trial looking at whether stereotactic radiotherapy together with chemotherapy is a useful treatment for people with locally advanced bile duct cancer (ABC-07)Biliary tract cancerMalignant neoplasm of other and unspecified parts of biliary tractCancerISRCTN10639376niversity College London83
招募中
2 期
Cyberknife auto-planning high-dose intensity SBRT trialnon-small cell lung cancerJPRN-jRCTs032230014Onishi Hiroshi80
进行中（未招募）
1 期
Stereotactic body radiotherapy with immunotherapy in early stage non-small cell lung cancer: tolerability and lung effectson small-cell lung cancer (NSCLC) Stage: T1-3( =5cm)N0M0)EUCTR2016-005187-34-GBThe Royal Marsden NHS Foundation Trust31